Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 1:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 830 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety and Pharmacokinetics in Healthy Volunteer Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants

NCT07136103
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-277, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 12, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects

NCT06299410
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ITI-1284 10 mg, ITI-1284 20 mg
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 12, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DDI HV (ATV - Merck)

NCT00518297
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir, Atazanavir, Atazanavir + Raltegravir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 4, 2010 · Synced Oct 12, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects

NCT01287858
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AC430
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 12, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects

NCT01459250
View directory record Official record
Conditions
Renal Impairment
Interventions
AGO178C
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 12, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Selpercatinib (LY3527723) in Healthy Participants

NCT05338515
View directory record Official record
Conditions
Healthy
Interventions
Selpercatinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 12, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY03015 in Healthy Chinese and Caucasian Adult Subjects

NCT07671833
View directory record Official record
Conditions
Healthy Participants
Interventions
LY03015 (LPM3770164 extended-release tablets)
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 12, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose Ranging Escalation Study of Tramadol Hydrochloride in Healthy Volunteers

NCT01947920
View directory record Official record
Conditions
Healthy
Interventions
Tramadol HCl, 50 mg, Placebo
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Oct 12, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years

NCT06225115
View directory record Official record
Conditions
Cognitive Dysfunction, Schizophrenia
Interventions
KYN-5356, placebo
Drug
Lead sponsor
Kynexis B.V.
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 12, 2026, 1:26 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

GSK706769 A First Time in Human Study For Males and Females

NCT00539201
View directory record Official record
Conditions
Healthy Subjects
Interventions
GSK706769
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 19, 2010 · Synced Oct 12, 2026, 1:26 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

AZD1305 Single and Multiple Ascending Dose Study in Healthy Japanese and Caucasian Subjects

NCT00935025
View directory record Official record
Conditions
Healthy
Interventions
AZD1305, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 7, 2010 · Synced Oct 12, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects

NCT05085197
View directory record Official record
Conditions
Healthy
Interventions
STSA-1005 injection, Placebo
Drug
Lead sponsor
Staidson Biopharma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 12, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Safety, Tolerability and PK, PD of HPG1860 in Healthy Subjects

NCT04480697
View directory record Official record
Conditions
Healthy
Interventions
HPG1860
Drug
Lead sponsor
Hepagene (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 12, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease

NCT04365218
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
MEDI8367, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 12, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants

NCT04231513
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2814, E2814-matched placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
20 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
2
States / cities
Glendale, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 12, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects

NCT01702649
View directory record Official record
Conditions
Healthy Volunteers, Bacterial Infections
Interventions
RPX2003 (Biapenem), Placebo
Drug
Lead sponsor
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 12, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety Study of PT010 in Healthy Subjects

NCT02189304
View directory record Official record
Conditions
COPD
Interventions
PT010, PT009, Symbicort Turbohaler
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 12, 2026, 1:26 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants

NCT05475821
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-990, Placebo for ABBV-990
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 12, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects

NCT06036784
View directory record Official record
Conditions
Postbariatric Hypoglycemia
Interventions
MBX 1416 (Part A), MBX 1416 (Part B), Placebo, MBX 1416 (Part C)
Drug
Lead sponsor
MBX Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 12, 2026, 1:26 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects

NCT07675590
View directory record Official record
Conditions
Health Adult Subjects, Obesity & Overweight
Interventions
TIX100, Placebo
Drug
Lead sponsor
TIXiMED, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 12, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Mirikizumab (LY3074828) in Healthy Participants

NCT02568423
View directory record Official record
Conditions
Healthy
Interventions
Mirikizumab - IV, Mirikizumab - SC, Placebo - IV, Placebo - SC
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 64 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 12, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects

NCT01450046
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Vitamin E δ-Tocotrienol
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 7, 2016 · Synced Oct 12, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects

NCT03082235
View directory record Official record
Conditions
Healthy Participants
Interventions
E6742, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 12, 2026, 1:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

JNJ-41443532 Sex, Race, and Age Pharmacokinetic (PK) Study

NCT01105780
View directory record Official record
Conditions
Healthy
Interventions
Placebo, JNJ-41443532
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 12, 2026, 1:26 PM EDT